Bone Biologics Corp (BBLG): Nasdaq/NYSE listing notice — Bone Biologics receives Nasdaq delisting notice for bid price non-compliance

Bone Biologics Corp

Received Nasdaq staff determination to delist due to failure to maintain $1.00 minimum bid price.
Company plans to request a hearing before Nasdaq Hearings Panel to appeal the delisting determination.
Company is evaluating alternatives to regain compliance; no assurance of success.
If delisted, securities expected to trade on OTC Markets platform.
Company previously under mandatory Panel Monitor, making it ineligible for standard compliance period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Bone Biologics Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

September 27, 2023, Bone Biologics Corporation (the “Company”) received a written notice (the “Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it failed to comply with the $1.00 per share minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As a result of the imposition of a mandatory Panel Monitor, as previously disclosed on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on May 19, 2023, the Company is not eligible for a compliance period to regain compliance with the minimum bid price requirement. Acco

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Bone Biologics Corp filing history →

Source: SEC EDGAR

accession 0001493152-23-034907

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.